07:00 , Oct 5, 2009 |  BioCentury  |  Finance

Ebb & Flow

Of the $6.9 billion in biotech debt raised thus far in 2009, $1.9 billion (28%) was raised in the last two weeks through four financings: three bumped up deals by Elan Corp. plc (NYSE:ELN), Incyte...
08:00 , Feb 2, 2009 |  BioCentury  |  Strategy

Imminent generic competition

Imminent generic competition Pfizer drug U.S. patent expiry 2008 U.S. revenues 2008 global revenues Aricept 2010 $20 (A) $482 (A) Lipitor 2010 $6,332 $12,401...
07:00 , May 28, 2007 |  BC Week In Review  |  Clinical News

Lybrel levonorgestrel/estradiol regulatory update

FDA approved Lybrel, an oral low-dose combination of levonorgestrel and ethinyl estradiol as a continuous contraceptive to prevent pregnancy. WYE plans to launch Lybrel, which is taken 365 days a year without a placebo or...
08:00 , Jan 13, 2003 |  BioCentury  |  Finance

Biotech coverage in Europe

Biotech coverage in Europe Bank Bankers Analysts ABN-AMRO Tommy Erdei; Ton Gardeniers; Vijay Karwal; Claus May; Dirk Siewert Adrian Howd Baden-Wurttembergische Bank None dedicated Christine Feller; Peter Herrmanns; Michael Leineweber; Oliver Schwarz Banc of...
07:00 , May 28, 2002 |  BioCentury  |  Strategy

Building bulk in vaccines

The acquisition of profitable vaccine company Rhein Biotech N.V. by Berna Biotech AG will create Europe's sixth largest biotech company with a market cap in the region of E820 million ($755 million). Last week's deal...
08:00 , Feb 25, 2002 |  BC Week In Review  |  Company News

Berna management update

Berna Biotech Ltd. (SWX:BBIN), Bern, Switzerland   Business: Infectious diseases   Hired: Anya Ramalho as head of business development and investor relations, formerly a life sciences analyst at Puilaetco Investment Bank   ...